Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis

NCT02478268 | Completed Phase 1 DMC

• 2 other identifiers: Pro00060259R01HL126771
• Study Type: interventional
• Target: 64
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of this study is to determine whether magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas, and conventional contrast can help visualize impaired lung function and detect changes over time in patients receiving treatment as well as those who don't. 129Xe is a special type of xenon gas and when inhaled during MRI may be able to show areas of abnormal thickening of parts of the lungs. These images combined with images taken with injected contrast agents or other types of MRI may provide a better way to look at lung structure and function in patients with IPF. The ultimate goal is to predict how a particular patient might respond to a particular therapy and to observe such responses earlier than conventional tests. The investigators anticipate that the images acquired in this study will provide more specific information about lung disease than standard lung function tests. The use of 129Xe MRI is investigational. "Investigational" means that these tests have not yet been approved by the US Food and Drug Administration and are being tested in research studies like this one. In addition, standard MRI with contrast is not typically done as standard of care for monitoring progression of IPF, therefore, its use in this study is also considered investigational. Healthy volunteers are being asked to participate in this study because the investigators need to develop a database of functional images that are representative of healthy lungs.

Conditions

Idiopathic Pulmonary Fibrosis

Keywords

idiopathic pulmonary fibrosis; xenon gas

Outcome Measures

Primary Outcomes (1)

• Change in lung function as measured by ventilation defect percentage (VDP)

  We expect that 129Xe ventilation defect percentage, and 129Xe ventilated lung volume measured 3 months after baseline, will predict CT progression observed 12 months from baseline

  12 months

Secondary Outcomes (1)

• Change in lung function as measured by gas exchange defect percentage (EDP)

  12 months

Study Arms (2)

Patients with idiopathic pulmonary fibrosis

ACTIVE COMPARATOR

Drug: Hyperpolarized 129-Xenon gas; Device: MRI

Healthy volunteers

ACTIVE COMPARATOR

Drug: Hyperpolarized 129-Xenon gas; Device: MRI

Interventions

Hyperpolarized 129-Xenon gas DRUG

Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.

Also known as: Hyperpolarized 129Xe

Healthy volunteers; Patients with idiopathic pulmonary fibrosis

MRI DEVICE

Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.

Healthy volunteers; Patients with idiopathic pulmonary fibrosis

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy volunteer (technical optimization)
• Outpatients of either gender, age \> 18.
• Willing and able to give informed consent and adhere to visit/protocol schedules. (Consent must be given before any study procedures are performed.)
• Clinical diagnosis of IPF by established means

You may not qualify if:

• Subject is less than 18 years old
• MRI is contraindicated based on responses to MRI screening questionnaire
• Subject is pregnant or lactating
• Respiratory illness of a bacterial or viral etiology within 30 days of MRI
• Subject has any form of known cardiac arrhythmia
• Subject does not fit into 129Xe vest coil used for MRI
• Subject cannot hold his/her breath for 15 seconds
• Subject deemed unlikely to be able to comply with instructions during imaging
• Recent exacerbation (within 30 days) defined by the need for antibiotics and/or systemic steroids
• Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements

Sponsors & Collaborators

• Bastiaan Driehuys: lead
• University of Wisconsin, Madison: collaborator
• National Heart, Lung, and Blood Institute (NHLBI): collaborator

Study Sites (2)

Duke University Medical Center

Durham, North Carolina, 27713, United States

Location

University of Wisconsin Madison

Madison, Wisconsin, 53792, United States

Location

MeSH Terms

Conditions

Idiopathic Pulmonary Fibrosis

Condition Hierarchy (Ancestors)

Pulmonary Fibrosis; Lung Diseases, Interstitial; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Joseph Mammarappallil, M.D.

  Duke University

  PRINCIPAL INVESTIGATOR

• Bastiaan Driehuys, Ph.D.

  Duke University

  STUDY DIRECTOR

• Sean B Fain, Ph.D.

  University of Wisconsin, Madison

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Associate Professor of Radiology

Study Record Dates

• First Submitted: June 16, 2015
• First Posted: June 23, 2015
• Study Start: May 1, 2015
• Primary Completion: September 26, 2020
• Study Completion: September 26, 2020
• Last Updated: October 11, 2021

Record last verified: 2021-10

Locations

US (2)